Thromboxane A2 receptor (TBXA2R)

The Thromboxane A2 (TXA2) pathway is a critical signaling cascade in cardiovascular physiology, primarily mediated by the enzyme Thromboxane A synthase (TBXAS1) and the Thromboxane A2 receptor (TBXA2R, also known as the TP receptor) (MedlinePlus, Wikipedia). TBXAS1 converts prostaglandin H2 into TXA2, a potent but short-lived lipid mediator that induces platelet aggregation and vascular smooth muscle contraction (NIH, irjpl.org). These effects are executed through the activation of the TP receptor, a G protein-coupled receptor (GPCR) expressed on platelets and vascular cells (ResearchGate, Patsnap). Dysregulation of this pathway is strongly linked to atherothrombotic events, including myocardial infarction and stroke, as well as inflammatory conditions and cancer progression (NIH, Frontiers). Pharmacological modulation of the pathway includes the use of aspirin to inhibit TXA2 synthesis, specific thromboxane synthase inhibitors like ozagrel, and TP receptor antagonists like ramatroban, which aim to prevent pathological thrombosis while minimizing bleeding risks (DrOracle, NIH).

Other names

Thromboxane A2 pathway componentsTP receptorThromboxane prostanoid receptorTXA2 receptorThromboxane A synthase 1TBXAS1TXASCYP5A1BDPLT13BDPLT14

Inhibition of Thromboxane A synthase (TBXAS1) to prevent TXA2 synthesis; Antagonism of the Thromboxane A2 receptor (TBXA2R) to block TXA2-mediated signaling; Irreversible inhibition of Cyclooxygenase-1 (COX-1) to reduce the precursor prostaglandin H2.